Baxter International (BAX) : Baxter International (BAX) had a healthy money flow of $1.07 million into the stock during the Fridays trading session. The value of bullish trades on upticks was $6.33 million, whereas, investors only sold shares worth $5.26 million on downticks. The stock closed the day with an up-down ratio of 1.2.The money flow in the block trades to the tune of $2.12 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $2.12 million worth of transactions were on upticks. Baxter International (BAX) stock slid $0.06 intraday and traded at 46.12, a change of -0.13% over previous days close. However, for the week, the company shares are -2.25% compared to previous weeks close.
The company Insiders own 1.08% of Baxter International shares according to the proxy statements. Institutional Investors own 85.74% of Baxter International shares.
In a related news, Almeida Jose E, CEO of Baxter International Inc, had purchased 11,691 shares on May 23, 2016. The total value of the transaction was $499,790. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Baxter International (NYSE:BAX): The stock opened at $46.38 and touched an intraday high of $46.44 on Friday. During the day, the stock corrected to an intraday low of $46.08, however, the bulls stepped in and pushed the price higher to close in the green at $46.28 with a gain of 0.22% for the day. The total traded volume for the day was 3,081,365. The stock had closed at $46.18 in the previous trading session.
Baxter International (BAX) : During the past 4 weeks, traders have been relatively bearish on Baxter International (BAX), hence the stock is down -3.58% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.4% relative to the S&P 500. The 4-week change in the price of the stock is -3.7% and the stock has fallen -1.91% in the past 1 week.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.